Natco Pharma launches generic hepatitis C drug in India

NEW DELHI: Natco Pharma today said it has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets, used for treatment of chronic hepatitis C, in India.

The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name 'Velpanat', Natco Pharma said in a BSE filing.

The company's product is generic version of Gilead Sciences Inc's Epclusa tablets.

Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis, Natco Pharma said.

Natco priced its generic tablets at an MRP of Rs 18,500 for a bottle of 28 tablets in India, the company said.

The company "has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.

Shares of Natco Pharma were trading 0.77 per cent up at Rs 908.50 on BSE.